Pfizer/Biontech’s preprint might prove academic as investors look to pivotal study designs and readouts.
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.
The latest Covid-19 vaccine award sees Glaxo and Sanofi score a $2.1bn windfall from the US government.
The deal-hungry French big pharma gives Translate’s mRNA vaccine technology a massive boost.
Merck & Co might have got off to a slow start, but now hopes to make up for lost time with multiple projects.
Moderna becomes the latest coronavirus vaccine player to act on the need for a major manufacturing push.
What is biopharma doing to develop vaccines against Covid-19, and what are the properties of each approach? Vantage takes a look.
Biotech IPOs raised a huge $2.3bn on Western exchanges in the second-quarter of 2018, as private companies rushed to market ahead of the summer lull.